Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric Subjects With Primary Immunodeficiency Diseases
Sponsor: Baxalta Innovations GmbH, now part of Shire
Listed as NCT03277313, this PHASE3 trial focuses on Primary Immunodeficiency Diseases (PID) and remains completed. Sponsored by Baxalta Innovations GmbH, now part of Shire, it has been updated 15 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2022 — Nov 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 10 earlier versions
-
Sep 2021 — Oct 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Sep 2019 — May 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — Apr 2018 [monthly]
Recruiting PHASE3
-
Nov 2017 — Mar 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2017 — Nov 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Sep 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baxalta Innovations GmbH, now part of Shire
- Baxalta now part of Shire
For direct contact, visit the study record on ClinicalTrials.gov .